Phase III study of Momelotinib in Patients with Myelofibrosis

• Research type

  Research Study

• Full title

  A Phase 3, Randomized Study to Evaluate the Efficacy of Momelotinib versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis who were Treated with Ruxolitinib.

• IRAS ID

  154982

• Contact name

  Joanne Ewing

• Contact email

  joanne.ewing@heartofengland.nhs.uk

• Sponsor organisation

  Gilead Sciences, Inc.

• Eudract number

  2013-005007-13

• REC name

  West Midlands - Edgbaston Research Ethics Committee

• REC reference

  14/WM/0170

• Date of REC Opinion

  29 Jul 2014

• REC opinion

  Further Information Favourable Opinion